Endotoxin fever in granulocytopenic rats: evidence that brain cyclooxygenase-2 is more important than circulating prostaglandin E(2).
PGE(2) is a recognized mediator of many fevers, and cyclooxygenase (COX) is the major therapeutic target for antipyretic therapy. The source, as well as the site of action of PGE(2), as an endogenous pyrogen, is widely accepted as being central, but PGE(2) in the circulation, possibly from leukocytes, may also contribute to the development of fever. However, bacterial infections are important causes of high fever in patients receiving myelosuppressive chemotherapy, and such fevers persist despite the use of COX inhibitors. In the study reported here, the febrile response to bacterial LPS was measured in rats made leukopenic by cyclophosphamide. A striking increase in LPS fever occurred in these granulocytopenic rats when compared with febrile responses in normal animals. Unlike LPS fever in normal rats, fever in granulocytopenic rats was neither accompanied by an increase in blood PGE(2) nor inhibited by ibuprofen. Both leukopenic and normal rats showed LPS-induced COX-2-immunoreactivity in cells associated with brain blood vessels. Furthermore, LPS induced an increase of PGE(2) in cerebrospinal fluid. Induction of COX-2-expression and PGE(2) production was inhibited by ibuprofen in normal but not in leukopenic rats. Although the results presented are, in part, confirmatory, they add new information to this field and open a number of important questions as yet unresolved. Overall, the present results indicate that, in contrast to immunocompetent rats, leukocytes and/or other mechanisms other than PGE(2) are implicated in the mechanisms restricting and reducing the enhanced febrile response to endotoxin in immunosuppressed hosts.
Tavares
Eva
E
Laboratory for Clinical and Experimental Pharmacology, University Hospital of Valme, Avda Bellavista s/n, Seville 41014, Spain.
Miñano
Francisco J
FJ
Maldonado
Rosario
R
Dascombe
Michael J
MJ
D000818:Animals; D001424:Bacterial Infections / Q000097:blood / Q000134:cerebrospinal fluid / Q000201:enzymology / Q000209:etiology / Q000473:pathology; D001921:Brain / Q000098:blood supply / Q000201:enzymology* / Q000473:pathology; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D015232:Dinoprostone / Q000097:blood / Q000134:cerebrospinal fluid; D005334:Fever / Q000097:blood / Q000134:cerebrospinal fluid / Q000139:chemically induced / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D006801:Humans; D007052:Ibuprofen / Q000494:pharmacology; D016867:Immunocompromised Host; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007970:Leukopenia / Q000097:blood / Q000134:cerebrospinal fluid / Q000139:chemically induced / Q000201:enzymology* / Q000473:pathology; D008070:Lipopolysaccharides / Q000633:toxicity*; D051381:Rats; D017208:Rats, Wistar
D016861:Cyclooxygenase Inhibitors; D008070:Lipopolysaccharides; D051546:Cyclooxygenase 2; C489691:Ptgs2 protein, rat; D015232:Dinoprostone; D007052:Ibuprofen